Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial

Taylor, Graham P.; Goon, Peter; Furukawa, Yoshitaka; Green, Hannah; Barfield, Anna; Mosley, Adam; Nose, Hirohisa; Babiker, Abdel; Rudge, Peter; Usuku, Koichiro; Osame, Mitsuhiro; Bangham, Charles R. M.; Weber, Jonathan

doi:10.1186/1742-4690-3-63

Cited by 104 publications

(64 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Reports have showed the limited value of corticosteroids, interferon-alpha and interferon-beta1a [63][64][65]. The combination of two nucleoside analogs (zidovudine and lamivudine) has been evaluated in a randomized, double-blind, placebo-controlled study with 16 HAM/TSP patients and no clinical improvement was observed [66]. Such treatment could be more effective in the early phases of the disease [60].…”

Section: Treatmentmentioning

confidence: 99%

HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Inflammatory Network

Gonçalves¹,

Proietti²,

Barbosa-Stancioli³

et al. 2008

IADT

View full text Add to dashboard Cite

| HAM/TSP patients experience impaired functional capacity. The use of categorical scales to accurately describe motor ability in these patients has been questioned. Aim: To evaluate the functional capacity of HAM/TSP patients by using the individual tests comprising the GDLAM protocol. Methods: Cross-sectional study carried out in the CHTLV, Salvador, Brazil. Functional capacity was evaluated using the tests of the GDLAM protocol (timed 10-minute walk, getting up from a sitting position, rising from a prone position, getting up from a chair, and moving around the house). Functional classifications were made by comparing patient performance to that of uninfected control individuals. Results: Twenty-four HAM/TSP and 25 healthy individuals were enrolled. Only 75% HAM/TSP patients completed the GDLAM protocol. Six patients failed to perform the RPP test. Timed measurements were significantly higher in the HAM/ TSP patients in comparison to uninfected controls. Conclusion: The use of alternative methods, such as the individual tests comprising the GDLAM protocol, may more accurately assess motor function in HAM/ TSP patients.

show abstract

Section: Treatmentmentioning

confidence: 99%

HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Inflammatory Network

Gonçalves¹,

Proietti²,

Barbosa-Stancioli³

et al. 2008

IADT

View full text Add to dashboard Cite

show abstract

“…However, clinical studies showed no improvement in outcomes even when combination (AZT + 3TC) nucleoside reverse-transcriptase inhibitor therapy was used. 24 In contrast to these findings, a more recently published case of donor-derived HTLV-I infection and HAM/TSP in a renal transplant recipient, who was treated with the same antiretroviral combination (AZT + 3TC) and tapering course of steroids, reports some clinical improvement after 3 months of therapy. Long-term data on this patient are, however, lacking.…”

Section: Discussionmentioning

confidence: 91%

Postrenal Transplant Human T-Cell Lymphotropic Virus Type I–Associated Myelopathy/Tropical Spastic Paraparesis

Torres

Taimur

2015

Transplantation Direct

View full text Add to dashboard Cite

We report a case of human T-cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP), in a 59 year-old, living-donor, renal transplant recipient from Jamaica. The patient's renal transplant had been performed 11 years ago, and her organ donor was also from Jamaica. Pretransplant HTLV-I serologic status for both the donor and recipient was unknown. The prevalence of HTLV-I seropositivity in the United States and Europe is low, and HAM/TSP is a rare occurrence. The positive predictive value of HTLV-I screening in these regions is therefore, low. This has generated debate among transplant societies regarding universal screening for HTLV-I before solid organ transplantation. Very limited evidence is available for the prevention and treatment of this devastating condition. Our case highlights the importance of selected pretransplant screening for HTLV-I infection among organ donors and candidates from endemic areas. We feel such testing may aid in the early recognition of HAM/TSP and more timely initiation of treatment.

show abstract

“…From the point of view of antiretroviral therapy, several studies have evaluated the role of zidovudine, lamivudine (in patients with or without myelopathy) [111] and raltegravir, with dissimilar and generally poor results. This is not surprising considering the higher levels of viral reproduction by division of infected cells than by intracellular viral replication.…”

Section: Treatmentmentioning

confidence: 99%

Infection with human retroviruses other than HIV-1: HIV-2, HTLV-1, HTLV-2, HTLV-3 and HTLV-4

Nicolás

Ambrosioni

Paredes

et al. 2015

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

HIV-1 is the most prevalent retrovirus, with over 30 million people infected worldwide. Nevertheless, infection caused by other human retroviruses like HIV-2, HTLV-1, HTLV-2, HTLV-3 and HTLV-4 is gaining importance. Initially confined to specific geographical areas, HIV-2, HTLV-1 and HTLV-2 are becoming a major concern in non-endemic countries due to international migration flows. Clinical manifestations of retroviruses range from asymptomatic carriers to life-threatening conditions, such as AIDS in HIV-2 infection or adult T-cell lymphoma/leukemia or tropical spastic paraparesis in HTLV-1 infection. HIV-2 is naturally resistant to some antiretrovirals frequently used to treat HIV-1 infection, but it does have effective antiretroviral therapy options. Unfortunately, HTLV still has limited therapeutic options. In this article, we will review the epidemiological, clinical, diagnostic, pathogenic and therapeutic aspects of infections caused by these human retroviruses.

show abstract

Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial

Cited by 104 publications

References 29 publications

HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Inflammatory Network

HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Inflammatory Network

Postrenal Transplant Human T-Cell Lymphotropic Virus Type I–Associated Myelopathy/Tropical Spastic Paraparesis

Infection with human retroviruses other than HIV-1: HIV-2, HTLV-1, HTLV-2, HTLV-3 and HTLV-4

Contact Info

Product

Resources

About